Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2014 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
CHRS on Nasdaq
Shares outstanding
116,964,738
Price per share
$1.42
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
51,568,692
Total reported value
$84,529,392
% of total 13F portfolios
0%
Share change
-3,717,047
Value change
-$2,975,454
Number of holders
111
Price from insider filings
$1.42
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 6.6% -30% $7,617,701 -$3,458,214 7,617,701 -31% BlackRock, Inc. 31 Mar 2025
Bering Partners II, L.P. 6.5% $12,468,441 7,602,708 Evgeny Zaytsev ("Zaytsev") 05 Sep 2025
SATTERFIELD THOMAS A JR 5.2% $6,009,514 6,009,514 Thomas A. Satterfield, Jr. 14 Apr 2025
Rubric Capital Management LP 4.6% $5,258,754 5,258,754 Rubric Capital Management LP 31 Dec 2024

As of 30 Sep 2025, 111 institutional investors reported holding 51,568,692 shares of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS). This represents 44% of the company’s total 116,964,738 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) together control 41% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 8.9% 10,459,986 -2.6% 0% $17,154,377
VANGUARD GROUP INC 8.8% 10,321,107 -2.4% 0% $16,926,616
TANG CAPITAL MANAGEMENT LLC 4.4% 5,097,362 0% 0.32% $8,359,674
Kohlberg Kravis Roberts & Co. L.P. 2.6% 3,036,076 0% 0.08% $4,931,401
GEODE CAPITAL MANAGEMENT, LLC 2.3% 2,741,226 +2.4% 0% $4,496,453
STATE STREET CORP 1.9% 2,223,376 +0.22% 0% $3,646,337
CM Management, LLC 1.8% 2,100,000 -6.7% 2.9% $3,444,000
C WorldWide Group Holding A/S 1.6% 1,928,464 0% 0.05% $3,163,000
PANAGORA ASSET MANAGEMENT INC 1.2% 1,375,968 +73% 0.01% $2,256,588
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.85% 993,092 +1.2% 0% $1,628,671
AQR CAPITAL MANAGEMENT LLC 0.77% 903,037 +17% 0% $1,480,981
MACQUARIE GROUP LTD 0.77% 899,999 0% 0% $1,476,000
NORTHERN TRUST CORP 0.73% 850,418 -5.1% 0% $1,394,685
Hudson Bay Capital Management LP 0.69% 810,000 -3% 0.01% $1,328,400
UBS Group AG 0.68% 795,941 +39% 0% $1,305,343
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.35% 403,913 +8.1% 0% $662,417
GOLDMAN SACHS GROUP INC 0.33% 382,780 +16% 0% $627,759
Bank of New York Mellon Corp 0.32% 376,685 -3.5% 0% $617,763
ROYAL BANK OF CANADA 0.29% 335,498 -1.3% 0% $551,000
CITADEL ADVISORS LLC 0.28% 331,155 +147% 0% $543,094
Jefferies Financial Group Inc. 0.28% 325,625 +2.5% 0% $534,025
STRS OHIO 0.28% 324,000 0% 0% $531,360
BARCLAYS PLC 0.25% 293,192 -1.5% 0% $480,835
Invesco Ltd. 0.22% 260,992 +25% 0% $428,027
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.22% 255,000 +78% 0.01% $418,200

Institutional Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 217,906 $307,505 +$39,903 $1.42 9
2025 Q3 51,568,692 $84,529,392 -$2,975,454 $1.64 111
2025 Q2 55,358,578 $40,439,575 -$4,928,963 $0.73 109
2025 Q1 62,082,313 $50,064,190 -$6,457,989 $0.81 114
2024 Q4 65,594,814 $90,489,403 -$12,493,801 $1.38 121
2024 Q3 76,943,748 $79,924,458 -$11,982,900 $1.04 127
2024 Q2 82,580,425 $142,867,620 -$603,275 $1.73 132
2024 Q1 82,494,208 $197,162,680 -$5,908,937 $2.39 134
2023 Q4 81,477,441 $271,309,409 -$37,399,801 $3.33 153
2023 Q3 92,968,604 $347,619,918 +$14,526,156 $3.74 168
2023 Q2 86,685,207 $370,290,994 +$30,644,927 $4.27 159
2023 Q1 78,433,333 $536,456,842 -$2,030,485 $6.84 163
2022 Q4 78,672,183 $622,985,097 +$2,380,758 $7.92 160
2022 Q3 77,664,501 $746,258,214 -$14,908,210 $9.61 168
2022 Q2 78,904,235 $571,951,639 +$12,362,063 $7.24 171
2022 Q1 75,936,074 $979,679,788 -$19,093,537 $12.91 172
2021 Q4 76,732,060 $1,226,275,602 +$9,148,757 $15.96 190
2021 Q3 76,118,247 $1,224,124,361 -$23,896,897 $16.07 182
2021 Q2 77,861,825 $1,077,307,964 -$38,365,571 $13.83 184
2021 Q1 80,296,427 $1,174,206,082 -$126,382,516 $14.61 201
2020 Q4 86,846,381 $1,509,532,138 +$7,068,870 $17.38 191
2020 Q3 87,967,283 $1,615,322,964 -$17,575,985 $18.34 200
2020 Q2 86,666,598 $1,547,355,972 +$228,840,811 $17.86 187
2020 Q1 74,669,838 $1,211,513,949 +$27,802,781 $16.22 185
2019 Q4 72,711,303 $1,309,075,614 +$50,544,709 $18.00 184
2019 Q3 69,362,054 $1,405,299,052 +$54,882,205 $20.26 165
2019 Q2 66,788,293 $1,473,155,747 +$29,409,971 $22.10 145
2019 Q1 68,742,401 $937,662,508 +$43,941,561 $13.64 114
2018 Q4 65,705,169 $594,602,586 -$13,874,058 $9.05 107
2018 Q3 63,584,248 $1,049,141,419 +$28,536,991 $16.50 106
2018 Q2 61,953,349 $867,373,516 +$96,221,276 $14.00 112
2018 Q1 55,290,055 $610,960,009 +$32,866,184 $11.05 102
2017 Q4 49,467,518 $435,305,054 +$17,238,403 $8.80 92
2017 Q3 46,927,893 $626,702,945 +$87,202,617 $13.35 90
2017 Q2 40,123,971 $575,784,532 +$26,148,562 $14.35 105
2017 Q1 37,510,462 $793,275,948 +$210,973,219 $21.15 109
2016 Q4 29,921,898 $842,300,808 +$50,764,547 $28.15 122
2016 Q3 28,142,776 $753,581,042 +$78,368,033 $26.78 116
2016 Q2 25,321,897 $427,677,064 +$112,113,002 $16.89 86
2016 Q1 18,234,639 $387,025,000 +$29,114,088 $21.23 74
2015 Q4 16,721,851 $383,952,785 +$8,941,726 $22.96 76
2015 Q3 16,091,708 $322,474,715 +$17,279,435 $20.04 76
2015 Q2 15,045,116 $433,747,071 +$223,061,016 $28.90 73
2015 Q1 7,268,421 $221,671,439 -$28,139,852 $30.58 49
2014 Q4 9,850,113 $157,559,817 +$157,548,817 $16.32 37